{"id":52202,"date":"2025-12-29T21:12:24","date_gmt":"2025-12-29T13:12:24","guid":{"rendered":"https:\/\/flcube.com\/?p=52202"},"modified":"2025-12-29T21:12:25","modified_gmt":"2025-12-29T13:12:25","slug":"luye-pharma-divests-25-nanjing-luye-stake-in-rmb-1-1-billion-complex-option-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52202","title":{"rendered":"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal"},"content":{"rendered":"\n<p><strong>Luye Pharma Group LTD<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2186:HKG\">HKG: 2186<\/a>) announced that its subsidiary <strong>Nanjing Luye<\/strong>, the Divesting Investors, and <strong>NJ Xinshi<\/strong> have entered into an <strong>Equity Transfer Agreement<\/strong>, whereby NJ Xinshi will acquire a <strong>25% equity interest<\/strong> in Nanjing Luye for <strong>RMB 1.086\u202fbillion<\/strong> (US$151\u202fmillion). The transaction features a complex <strong>put\/call option structure<\/strong> involving <strong>China Cinda<\/strong> and guarantees from Luye Pharma, creating a strategic financing vehicle for Nanjing Luye while retaining future repurchase flexibility.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Seller<\/strong><\/td><td>Divesting Investors (Luye Pharma affiliates)<\/td><\/tr><tr><td><strong>Buyer<\/strong><\/td><td>NJ Xinshi (limited partnership)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>25% equity interest in Nanjing Luye<\/td><\/tr><tr><td><strong>Consideration<\/strong><\/td><td><strong>RMB 1,086,383,600<\/strong> (US$151\u202fmillion)<\/td><\/tr><tr><td><strong>Transaction Date<\/strong><\/td><td>28\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Off-balance-sheet financing with optionality for future repurchase<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ownership-structure-amp-partnership-agreements\">Ownership Structure &amp; Partnership Agreements<\/h2>\n\n\n\n<p><strong>NJ Xinshi Partnership Composition<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Shandong Luye<\/strong> (Luye Pharma affiliate): <strong>33.2%<\/strong> interest (RMB\u202f200\u202fmillion invested Oct\u202f2025)<\/li>\n\n\n\n<li><strong>China Cinda<\/strong>: <strong>66.4%<\/strong> interest (limited partner)<\/li>\n\n\n\n<li><strong>Hangzhou Xinshi &amp; Yantai Hexin<\/strong>: <strong>0.2%<\/strong> each (general partners)<\/li>\n<\/ul>\n\n\n\n<p><strong>Key Agreements<\/strong>:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Nanjing Luye Equity Option Agreement<\/strong>: NJ Xinshi has the <strong>right to require Yantai Luye<\/strong> to repurchase its 25% Nanjing Luye stake upon certain trigger events<\/li>\n\n\n\n<li><strong>Partnership Distribution Obligation<\/strong>: NJ Xinshi must make <strong>semi\u2011annual distributions<\/strong> to China Cinda<\/li>\n\n\n\n<li><strong>Guarantee Structure<\/strong>: <strong>Luye Pharma and Shenzhen Luye<\/strong> provide <strong>joint and several guarantees<\/strong> to China Cinda and Hangzhou Xinshi for Yantai Luye\u2019s obligations<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-complex-option-mechanisms\">Complex Option Mechanisms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Option Type<\/th><th>Holder<\/th><th>Trigger Event<\/th><th>Obligation<\/th><\/tr><\/thead><tbody><tr><td><strong>Put Option<\/strong><\/td><td>China Cinda<\/td><td>Material breach, performance shortfall, exit demand<\/td><td>Yantai Luye must purchase China Cinda\u2019s 66.4% NJ Xinshi interest<\/td><\/tr><tr><td><strong>Call Option<\/strong><\/td><td>Yantai Luye<\/td><td>Strategic decision, financing optimization<\/td><td>Yantai Luye may purchase China Cinda\u2019s interest; must simultaneously acquire Hangzhou Xinshi\u2019s 0.2%<\/td><\/tr><tr><td><strong>Nanjing Luye Repurchase Option<\/strong><\/td><td>NJ Xinshi<\/td><td>Predefined performance or market conditions<\/td><td>Yantai Luye must repurchase the 25% Nanjing Luye stake at formulaic valuation<\/td><\/tr><tr><td><strong>Distribution Shortfall Guarantee<\/strong><\/td><td>Yantai Luye<\/td><td>NJ Xinshi fails to pay China Cinda<\/td><td>Yantai Luye covers any unpaid semi\u2011annual distributions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Simultaneous Purchase Requirement<\/strong>: Exercise of either China Cinda\u2019s <strong>Put Option<\/strong> or Yantai Luye\u2019s <strong>Call Option<\/strong> obligates Yantai Luye to also acquire <strong>Hangzhou Xinshi\u2019s<\/strong> 0.2% general partnership interest, ensuring clean capital structure transitions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications-amp-capital-structure\">Financial Implications &amp; Capital Structure<\/h2>\n\n\n\n<p><strong>Nanjing Luye Valuation<\/strong>: The <strong>RMB 1.086\u202fbillion<\/strong> price for 25% equity implies a <strong>pre\u2011money valuation of RMB 4.345\u202fbillion<\/strong> (US$605\u202fmillion) for Nanjing Luye, representing a <strong>2.8x premium<\/strong> to its carrying value on Luye Pharma\u2019s books.<\/p>\n\n\n\n<p><strong>Debt Financing<\/strong>: Upon transaction completion, <strong>NJ Xinshi will secure a bank facility of up to RMB 648\u202fmillion<\/strong> (US$90\u202fmillion), likely used to fund the equity purchase and provide working capital for Nanjing Luye\u2019s operations.<\/p>\n\n\n\n<p><strong>Accounting Treatment<\/strong>: The <strong>put\/call structure<\/strong> and guarantee arrangements suggest <strong>consolidation<\/strong> of Nanjing Luye remains on Luye Pharma\u2019s balance sheet, with the RMB\u202f1.086\u202fbillion recorded as a <strong>financing liability<\/strong> rather than divestiture gain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-investor-takeaways\">Strategic Rationale &amp; Investor Takeaways<\/h2>\n\n\n\n<p><strong>Motivation for Complex Structure<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Off\u2011Balance\u2011Sheet Financing<\/strong>: Raises RMB\u202f1.1\u202fbillion without immediate equity dilution at parent level<\/li>\n\n\n\n<li><strong>Future Flexibility<\/strong>: Call option allows Luye to <strong>reacquire full control<\/strong> when strategic value crystallizes<\/li>\n\n\n\n<li><strong>State\u2011Back Partnership<\/strong>: China Cinda\u2019s involvement provides <strong>implicit credit enhancement<\/strong> and potential policy support<\/li>\n\n\n\n<li><strong>Capital Recycling<\/strong>: Enables Nanjing Luye to <strong>accelerate R&amp;D<\/strong> while Luye Pharma retains operational control<\/li>\n<\/ul>\n\n\n\n<p><strong>Risk Factors<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Put Option Trigger<\/strong>: Underperformance could force <strong>mandatory repurchase<\/strong>, straining Luye Pharma liquidity<\/li>\n\n\n\n<li><strong>Guarantee Exposure<\/strong>: Joint guarantees create <strong>contingent liability<\/strong> of up to <strong>RMB\u202f1.7\u202fbillion<\/strong> (purchase + facility)<\/li>\n\n\n\n<li><strong>Regulatory Scrutiny<\/strong>: Complex structures may attract <strong>CSRC review<\/strong> related to related\u2011party transactions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-biotech-financing-trends\">Market Context: Biotech Financing Trends<\/h2>\n\n\n\n<p>China biotech <strong>private financing<\/strong> fell <strong>45%<\/strong> in 2025 vs. 2024; strategic partnerships with <strong>state\u2011owned asset managers<\/strong> (like China Cinda) have become a <strong>critical funding source<\/strong>, representing <strong>35%<\/strong> of total sector capital raised.<\/p>\n\n\n\n<p><strong>Comparable Transactions<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>InnoCare Pharma<\/strong> secured RMB\u202f800\u202fmillion via similar put\/call structure with <strong>CICC<\/strong> in Sep\u202f2025<\/li>\n\n\n\n<li><strong>BeiGene<\/strong> sold 20% stake in Guangzhou biologics unit to <strong>Ping An<\/strong> for RMB\u202f2.5\u202fbillion with repurchase rights (Aug\u202f2025)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the financial impact of the Nanjing Luye transaction, option exercise probabilities, and strategic implications for Luye Pharma\u2019s capital structure. Actual results may differ due to accounting treatment decisions, regulatory reviews, and Nanjing Luye\u2019s operational performance..<a href=\"https:\/\/flcube.com\/\"><\/a><a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025122800128_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025122800128_c.\"><\/object><a id=\"wp-block-file--media-39ace207-eeb7-48c3-ad6e-e49500fa34e2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025122800128_c.pdf\">2025122800128_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025122800128_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-39ace207-eeb7-48c3-ad6e-e49500fa34e2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52204,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1023,219],"class_list":["post-52202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-2186","tag-luye-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors, and NJ Xinshi have entered into an Equity Transfer Agreement, whereby NJ Xinshi will acquire a 25% equity interest in Nanjing Luye for RMB 1.086\u202fbillion (US$151\u202fmillion). The transaction features a complex put\/call option structure involving China Cinda and guarantees from Luye Pharma, creating a strategic financing vehicle for Nanjing Luye while retaining future repurchase flexibility.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52202\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal\" \/>\n<meta property=\"og:description\" content=\"Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors, and NJ Xinshi have entered into an Equity Transfer Agreement, whereby NJ Xinshi will acquire a 25% equity interest in Nanjing Luye for RMB 1.086\u202fbillion (US$151\u202fmillion). The transaction features a complex put\/call option structure involving China Cinda and guarantees from Luye Pharma, creating a strategic financing vehicle for Nanjing Luye while retaining future repurchase flexibility.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52202\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T13:12:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-29T13:12:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2906.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal\",\"datePublished\":\"2025-12-29T13:12:24+00:00\",\"dateModified\":\"2025-12-29T13:12:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202\"},\"wordCount\":678,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2906.webp\",\"keywords\":[\"HKG: 2186\",\"Luye Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52202#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52202\",\"name\":\"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2906.webp\",\"datePublished\":\"2025-12-29T13:12:24+00:00\",\"dateModified\":\"2025-12-29T13:12:25+00:00\",\"description\":\"Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors, and NJ Xinshi have entered into an Equity Transfer Agreement, whereby NJ Xinshi will acquire a 25% equity interest in Nanjing Luye for RMB 1.086\u202fbillion (US$151\u202fmillion). The transaction features a complex put\\\/call option structure involving China Cinda and guarantees from Luye Pharma, creating a strategic financing vehicle for Nanjing Luye while retaining future repurchase flexibility.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52202\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2906.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2906.webp\",\"width\":1080,\"height\":608,\"caption\":\"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52202#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors, and NJ Xinshi have entered into an Equity Transfer Agreement, whereby NJ Xinshi will acquire a 25% equity interest in Nanjing Luye for RMB 1.086\u202fbillion (US$151\u202fmillion). The transaction features a complex put\/call option structure involving China Cinda and guarantees from Luye Pharma, creating a strategic financing vehicle for Nanjing Luye while retaining future repurchase flexibility.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52202","og_locale":"en_US","og_type":"article","og_title":"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal","og_description":"Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors, and NJ Xinshi have entered into an Equity Transfer Agreement, whereby NJ Xinshi will acquire a 25% equity interest in Nanjing Luye for RMB 1.086\u202fbillion (US$151\u202fmillion). The transaction features a complex put\/call option structure involving China Cinda and guarantees from Luye Pharma, creating a strategic financing vehicle for Nanjing Luye while retaining future repurchase flexibility.","og_url":"https:\/\/flcube.com\/?p=52202","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T13:12:24+00:00","article_modified_time":"2025-12-29T13:12:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2906.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52202#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52202"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal","datePublished":"2025-12-29T13:12:24+00:00","dateModified":"2025-12-29T13:12:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52202"},"wordCount":678,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52202#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2906.webp","keywords":["HKG: 2186","Luye Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52202#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52202","url":"https:\/\/flcube.com\/?p=52202","name":"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52202#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52202#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2906.webp","datePublished":"2025-12-29T13:12:24+00:00","dateModified":"2025-12-29T13:12:25+00:00","description":"Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors, and NJ Xinshi have entered into an Equity Transfer Agreement, whereby NJ Xinshi will acquire a 25% equity interest in Nanjing Luye for RMB 1.086\u202fbillion (US$151\u202fmillion). The transaction features a complex put\/call option structure involving China Cinda and guarantees from Luye Pharma, creating a strategic financing vehicle for Nanjing Luye while retaining future repurchase flexibility.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52202#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52202"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52202#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2906.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2906.webp","width":1080,"height":608,"caption":"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52202#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2906.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52202"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52202\/revisions"}],"predecessor-version":[{"id":52205,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52202\/revisions\/52205"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52204"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}